Premium
Extended survival and remission rates in metastatic breast cancer
Author(s) -
van Dyk J. J.,
Falkson Geoffrey
Publication year - 1971
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197102)27:2<300::aid-cncr2820270208>3.0.co;2-g
Subject(s) - medicine , cyclophosphamide , oophorectomy , metastatic breast cancer , breast cancer , chemotherapy , survival rate , cancer , surgery , oncology , incidence (geometry) , hysterectomy , physics , optics
Seventy‐five premenopausal patients with metastatic breast cancer were treated by oophorectomy and various combinations, including cyclophosphamide, fluorouracil, methotrexate, vinca alkaloids, fluoxymesterone, and corticosteroids. Survival rates, from the start of cancer chemotherapy, for the patients were 61% at 2 years, 47% at 3 years, 30% at 4 years, and 20% at 5 years. This long survival time was proportional to extended remission rates, which were 73% at 1 year, 38% at 3 years, and 22% at 4 years. The survival and incidence of remission were better in patients who received cyclophosphamide at the time of oophorectomy as compared to those patients who were first treated by oophorectomy alone. Patients who received oophorectomy plus cyclophosphamide as first treatment for metastases had a 5‐year survival of 31%. The survival rate of patients treated within 2 months of the confirmation of distal metastases by cyclophosphamide plus oophorectomy was 57%.